EP300 and cancer: In disease- or cancer-induced muscle atrophy models, CBP/p300 is typically phosphorylated, and phosphorylated CBP/p300 enhances its acetyltransferase activity, leading to morphological and molecular changes associated with atrophy [150,151,152,153].